PURPOSE: Hypofractionated radiotherapy for prostate cancer is well established for definitive treatment, but not well defined in the postoperative setting. The purpose of this analysis was to assess oncologic outcomes and toxicity in a large cohort of patients treated with conventionally fractionated three-dimensional (3D) conformal radiotherapy (CF) and hypofractionated volumetric modulated arc therapy (HF) after radical prostatectomy. METHODS: Between 1994 and 2019, a total of 855 patients with prostate carcinoma were treated by postoperative radiotherapy using CF (total dose 65-72 Gy, single fraction 1.8-2 Gy) in 572 patients and HF (total dose 62.5-63.75 Gy, single fraction 2.5-2.55 Gy) in 283 patients. The association of treatment modality with biochemical control, overall survival (OS), and gastrointestinal (GI) and genitourinary (GU) toxicity was assessed using logistic and Cox regression analysis. RESULTS: There was no difference between the two modalities regarding biochemical control rates (77% versus 81%, respectively, for HF and CF at 24 months and 58% and 64% at 60 months; p = 0.20). OS estimates after 5 years: 95% versus 93% (p = 0.72). Patients undergoing HF had less frequent grade 2 or higher acute GI or GU side effects (p = 0.03 and p = 0.005, respectively). There were no differences in late GI side effects between modalities (hazard ratio 0.99). Median follow-up was 23 months for HF and 72 months for CF (p < 0.001). CONCLUSION: For radiation therapy of resected prostate cancer, our analysis of this largest single-centre cohort (n = 283) treated with hypofractionation with advanced treatment techniques compared with conventional fractionation did not yield different outcomes in terms of biochemical control and toxicities. Prospective investigating of HF is merited.

Center for Medical Statistics Informatics and Intelligent Systems Section for Medical Statistics Medical University of Vienna Vienna Austria

Department of Radiation Oncology Comprehensive Cancer Center Medical University of Vienna Währinger Gürtel 18 20 1090 Vienna Austria

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology University of Texas Southwestern Dallas TX USA

Departments of Urology Weill Cornell Medical College New York NY USA

Division of Nephrology and Dialysis Department of Internal Medicine III Medical University of Vienna Vienna Austria

Division of Urology Department of Special Surgery Jordan University Hospital The University of Jordan Amman Jordan

Institute for Urology and Reproductive Health 1 M Sechenov 1st Moscow State Medical University Moscow Russian Federation

See more in PubMed

Cornford P, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–282. doi: 10.1016/j.eururo.2020.09.046. PubMed DOI

Mohler JL, et al. NCCN clinical practice guidelines in oncology—prostate cancer version 4.2019. J Natl Compr Canc Netw. 2019 doi: 10.6004/jnccn.2019.0023. PubMed DOI

Van den Broeck T, van den Bergh RCN, Arfi N. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer : a systematic review. Eur Urol. 2019;75:967–987. doi: 10.1016/j.eururo.2018.10.011. PubMed DOI

Kneebone A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21:1331–1340. doi: 10.1016/S1470-2045(20)30456-3. PubMed DOI

Parker CC, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396:1413–1421. doi: 10.1016/S0140-6736(20)31553-1. PubMed DOI

Yu JB. Hypofractionated radiotherapy for prostate cancer: further evidence to tip the scales. J Clin Oncol. 2017;35:1867–1869. doi: 10.1200/JCO.2017.72.7016. PubMed DOI

Dearnaley D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047–1060. doi: 10.1016/S1470-2045(16)30102-4. PubMed DOI PMC

Sharfo AWM, et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiother Oncol. 2018;128:349–356. doi: 10.1016/j.radonc.2018.05.028. PubMed DOI

Cuccia F, et al. Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. Cancer Manag Res. 2018;10:5053–5060. doi: 10.2147/CMAR.S182016. PubMed DOI PMC

Barra S, et al. Moderate hypofractionated radiotherapy after prostatectomy for cancer patients: toxicity and clinical outcome. Cancer Manag Res. 2018;10:473–480. doi: 10.2147/CMAR.S146131. PubMed DOI PMC

Cozzarini C, et al. Higher-than-expected severe (grade 3–4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol. 2014;66:1024–1030. doi: 10.1016/j.eururo.2014.06.012. PubMed DOI

Tramacere F, et al. Postoperative hypofractionated radiotherapy for prostate cancer. Anticancer Res. 2018;38:2951–2956. PubMed

Kruser TJ, et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer. 2011;117:2629–2636. doi: 10.1002/cncr.25824. PubMed DOI PMC

Franzese C, et al. Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. Strahlenther Onkol. 2020 doi: 10.1007/s00066-020-01691-z. PubMed DOI

Macchia G, et al. Hypofractionated postoperative IMRT in prostate carcinoma: a phase I/II study. Anticancer Res. 2017;37:5821–5828. PubMed

Bolla M, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) Lancet. 2005;366:572–578. doi: 10.1016/S0140-6736(05)67101-2. PubMed DOI

Rana S, Cheng C. Radiobiological impact of planning techniques for prostate cancer in terms of tumor control probability and normal tissue complication probability. Ann Med Health Sci Res. 2014;4:167. doi: 10.4103/2141-9248.129023. PubMed DOI PMC

Roach M, et al. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the radiation therapy oncology group 9413 trial. Int J Radiat Oncol Biol Phys. 2006;66:647–653. doi: 10.1016/j.ijrobp.2006.05.074. PubMed DOI

Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC) Int. J. Radiat. Oncol. Biol. Phys. 1995;31:1341–1346. doi: 10.1016/0360-3016(95)00060-C. PubMed DOI

Cookson MS, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the re. J Urol. 2007;177:540–545. doi: 10.1016/j.juro.2006.10.097. PubMed DOI

Hwang WL, et al. Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol. 2018;4:1–8. PubMed PMC

Ost P, De Troyer B, Fonteyne V, Oosterlinck W, De Meerleer G. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;80:1316–1322. doi: 10.1016/j.ijrobp.2010.04.039. PubMed DOI

Katayama S, et al. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. Int J Radiat Oncol Biol Phys. 2014;90:926–933. doi: 10.1016/j.ijrobp.2014.07.015. PubMed DOI

Waldstein C, Dörr W, Pötter R, Widder J, Goldner G. Postoperative radiotherapy for prostate cancer: morbidity of local-only or local-plus-pelvic radiotherapy. Strahlenther Onkol. 2018;194:23–30. doi: 10.1007/s00066-017-1215-9. PubMed DOI PMC

Murthy V, et al. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial. Radiother Oncol. 2020;145:71–80. doi: 10.1016/j.radonc.2019.12.006. PubMed DOI

Sujenthiran A, et al. Treatment-related toxicity in men who received intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: a national population-based study. Radiother Oncol. 2018;128:357–363. doi: 10.1016/j.radonc.2018.04.032. PubMed DOI